S&P 500

5.346,99

-0,11%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Outlook Therapeutics Inc (OTLK)
Outlook Therapeutics Inc (OTLK) Notícias

OTLK

Outlook Therapeutics (OTLK)

Outlook Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:OTLK

1 2 3 4 5 6 7 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
28/05/2024	09:05	GlobeNewswire Inc.	Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD	NASDAQ:OTLK	Outlook Therapeutics Inc
15/05/2024	18:19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OTLK	Outlook Therapeutics Inc
15/05/2024	18:15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:OTLK	Outlook Therapeutics Inc
15/05/2024	18:00	GlobeNewswire Inc.	Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update	NASDAQ:OTLK	Outlook Therapeutics Inc
13/05/2024	09:50	GlobeNewswire Inc.	Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD	NASDAQ:OTLK	Outlook Therapeutics Inc
09/05/2024	09:45	GlobeNewswire Inc.	Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast	NASDAQ:OTLK	Outlook Therapeutics Inc
07/05/2024	01:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:OTLK	Outlook Therapeutics Inc
06/05/2024	17:09	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:OTLK	Outlook Therapeutics Inc
02/05/2024	10:05	GlobeNewswire Inc.	Outlook Therapeutics® to Present at the Retina World Congress 2024	NASDAQ:OTLK	Outlook Therapeutics Inc
29/04/2024	10:00	GlobeNewswire Inc.	Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	NASDAQ:OTLK	Outlook Therapeutics Inc
15/04/2024	17:15	GlobeNewswire Inc.	Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	NASDAQ:OTLK	Outlook Therapeutics Inc
22/03/2024	08:35	GlobeNewswire Inc.	Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	NASDAQ:OTLK	Outlook Therapeutics Inc
18/03/2024	18:10	GlobeNewswire Inc.	Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million	NASDAQ:OTLK	Outlook Therapeutics Inc
12/03/2024	09:05	GlobeNewswire Inc.	Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split	NASDAQ:OTLK	Outlook Therapeutics Inc
11/03/2024	17:43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:OTLK	Outlook Therapeutics Inc
14/02/2024	10:05	GlobeNewswire Inc.	Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update	NASDAQ:OTLK	Outlook Therapeutics Inc
08/02/2024	09:00	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:OTLK	Outlook Therapeutics Inc
08/02/2024	08:59	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:OTLK	Outlook Therapeutics Inc
31/01/2024	18:01	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:OTLK	Outlook Therapeutics Inc
31/01/2024	10:05	GlobeNewswire Inc.	Outlook Therapeutics® Doses First Subject in NORSE EIGHT	NASDAQ:OTLK	Outlook Therapeutics Inc
29/01/2024	19:00	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:OTLK	Outlook Therapeutics Inc
24/01/2024	19:00	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:OTLK	Outlook Therapeutics Inc
23/01/2024	10:00	GlobeNewswire Inc.	Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010	NASDAQ:OTLK	Outlook Therapeutics Inc
22/12/2023	19:00	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:OTLK	Outlook Therapeutics Inc
22/12/2023	10:05	GlobeNewswire Inc.	Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU	NASDAQ:OTLK	Outlook Therapeutics Inc
19/12/2023	10:05	GlobeNewswire Inc.	Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010	NASDAQ:OTLK	Outlook Therapeutics Inc
18/12/2023	07:45	PR Newswire (US)	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Outlook Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: OTLK)	NASDAQ:OTLK	Outlook Therapeutics Inc
06/12/2023	10:05	GlobeNewswire Inc.	Outlook Therapeutics® Announces Strategic Organizational Realignment	NASDAQ:OTLK	Outlook Therapeutics Inc
27/11/2023	10:05	GlobeNewswire Inc.	Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010	NASDAQ:OTLK	Outlook Therapeutics Inc
14/11/2023	10:05	GlobeNewswire Inc.	Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe	NASDAQ:OTLK	Outlook Therapeutics Inc